Investor Presentation
Repligen - A Bioprocessing Innovator
Enabling efficient, single-use, high productivity
biological drug manufacturing
37%
5-year
Revenue CAGR
(2015-2020)
Consistently
above average
industry growth
$3.7B+
Total Addressable
Market
An expanding
portfolio
scaling into clinical
and commercial
manufacturing
Expanding
applications
Serving multiple
biological drug classes
Monoclonal antibodies
Gene therapy
COVID-related vaccines
and therapeutics
Highly
differentiated
portfolio
through M&A and
R&D
Advancing disruptive
technologies
with market leadership
positions
RREPLIGEN
INSPIRING ADVANCES IN BIOPROCESSING
1,465
Employees
530K+
Sq. Ft. Mftg.
(6.30.21)
Investing in talent, systems
& capacity
~500 new employees 9M-21
3 Site Buildouts Ongoing
(US, Ireland)
4View entire presentation